Commencement (album)

22nd Century Group (XXII) Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
VLN, Nicotine, Table, Marketing, GVB, Research, Tobacco, Commencement (album), Pacific Century Group, CBG, Sale, Fourth, Old pal, Investment, Cost, Pinnacle, Webcast, XXII, Growth, Century, Health, FDA, Biomass, Letter, Adjustment, Second, Cannabidiol, Drug, Video game, Pharmaceutical industry, Retail, Whaling, Natural gas, Management, Tourism, Rare-earth element, CBD

Net revenues for the second quarter of 2023 were $23.4 million, an increase of 61.8% from the same period in 2022.

Key Points: 
  • Net revenues for the second quarter of 2023 were $23.4 million, an increase of 61.8% from the same period in 2022.
  • Gross profit for the second quarter of 2023 was $(2.3) million as compared to $0.9 million in the prior year period.
  • Gross margin is expected to improve in the second half of 2023 reflecting:
    New CDMO+D contracts to begin shipping product in the second half of 2023.
  • to discuss its second quarter 2023 financial results and business highlights.

Time Equities Inc. Unveils Vision and Commences Marketing for Emerald Park, its Ultra-Luxury Apartment Community in Panama City Beach, FL

Retrieved on: 
Monday, July 24, 2023
Emerald, TEI, Heart, School, Panama, Commencement (album), Bath, Coffee, Transport, Emerald Park, Barking Park, Property management, Hotel, Self storage, Beach

PANAMA CITY BEACH, Fla., July 24, 2023 /PRNewswire/ -- International real estate company Time Equities, Inc. (TEI) today announced it has launched a teaser website and preleasing campaign for 108 ultra-luxury new apartment homes at Emerald Park (www.emeraldparkpcb.com), its new residential apartment community in Panama City Beach, Florida.

Key Points: 
  • TEI will deliver the new units in phases, starting in late 2023 and continuing through the Spring of 2024.
  • In addition to the new units, Emerald Park will feature a market-leading suite of over 10,000 square feet of amenities, both interior and exterior.
  • Emerald Park is situated in the heart of Panama City Beach, on Front Beach Road at Laurie Avenue.
  • To learn more about Emerald Park and register on the priority list, visit the website at www.emeraldparkpcb.com .

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

Retrieved on: 
Tuesday, February 28, 2023
Biotechnology, CABE, Cancer, Services General Administration and Coordination Department, Government of Sindh, DSM-IV codes, Tada, Research, Research and development, Investment, CBQT-FM, Patient, R, Commencement (album), Liver, CBE, Pondok Cabe Airport, Hematology, AATD, Cytosine, Security (finance), Nature Biotechnology, C. E. T. Warren, ESCAPE, Administration, G&A, Pharmaceutical industry, Cryptocurrency, Beam

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reaffirmed its anticipated upcoming milestones across the company’s hematology, immunology-oncology, and genetic disease portfolios and reported fourth quarter and full year 2022 financial results.

Key Points: 
  • North Carolina Manufacturing Facility Open and Operational, Expected to Commence cGMP Operations in Late 2023
    Ended Fourth Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities
    CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reaffirmed its anticipated upcoming milestones across the company’s hematology, immunology-oncology, and genetic disease portfolios and reported fourth quarter and full year 2022 financial results.
  • Research & Development (R&D) Expenses: R&D expenses were $86.3 million for the fourth quarter of 2022 and $311.6 million for the full year ended December 31, 2022, compared to $96.8 million for the fourth quarter of 2021 and $387.1 million for the full year ended December 31, 2021.
  • General & Administrative (G&A) Expenses: G&A expenses were $22.7 million for the fourth quarter of 2022 and $87.8 million for the full year ended December 31, 2022, compared to $17.8 million for the fourth quarter of 2021 and $57.2 million for the full year ended December 31, 2021.
  • Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2022, will enable the company to fund its anticipated operating expenses and capital expenditure requirements at least into 2025.

Burgan Bank Selects Commencis as Its Technology Partner in Turkey

Retrieved on: 
Thursday, November 24, 2022
Software, Human, Heart, Burgan Bank, Insurance, Partnership, ON, Digital banking, Financial system, Ecosystem, Commencement (album), Acquisition, Online shopping

Burgan Bank's innovative and pioneering digital bank 'ON' in Turkey has signed a strategic business partnership with Commencis to further its vision of becoming the country's leading digital banking provider. This new partnership enables Commencis to bring its expertise to Burgan Mobile and ON on their digital transformation journey.

Key Points: 
  • This exciting collaboration with the Commencis team aims to design an end-to-end customer-oriented digital channel experience for ON's digital platform.
  • Commencis CEO Firat Isbecer, commented on the partnership with Burgan Bank, "Commencis continues to play a significant role in the digital transformation of the banking sector through its proprietary products and services.
  • We are thrilled to be afforded the opportunity to develop a long-term relationship with an innovator like Burgan Bank."
  • Commencis is an award-winning technology company helping leading brands grow and scale in digital, powered by its big data, analytics, and cloud products.

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 16, 2022
Protide, Immunogenic cell death, PD-1, NSCLC, Docetaxel, Oxaliplatin, European Society for Medical Oncology, Large-cell lung carcinoma, Melanoma, Patient, Neoplasm, Adenocarcinoma, Pembrolizumab, Oncology, Irinotecan, Thymidylate synthase, NCNA, Commencement (album), Security (finance), ESMO, Colorectal cancer, Cancer, Therapy, Pemetrexed, Bevacizumab, Organic acid, Pharmaceutical industry, Medical imaging, Food delivery

EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of September 30, 2022, NuCana had cash and cash equivalents of 50.8 million compared to 46.5 million as of June 30, 2022 and 60.3 million at December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 4.5 million for the quarter ended September 30, 2022, as compared to a net loss of 8.0 million for the quarter ended September 30, 2021.
  • Basic and diluted loss per share was 0.09 for the quarter ended September 30, 2022, as compared to 0.15 per share for the quarter ended September 30, 2021.

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 17, 2022
Protide, U.S. Securities and Exchange Commission, Forward-looking statement, GLOBE, Private Securities Litigation Reform Act, SEC, Cancer, PD-1, Patent, Sofosbuvir, Politics of Poland, Security (finance), Neoplasm, Compliance, Patient, Irinotecan, Company, Therapy, Bevacizumab, NASDAQ, Organic acid, Goal, Commencement (album), NCNA, Colorectal cancer, Terminology, Renewable energy, Pharmaceutical industry, Food delivery

EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of June 30, 2022, NuCana had cash and cash equivalents of 46.5 million compared to 52.6 million as of March 31, 2022 and 60.3 million at December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 3.9 million for the quarter ended June 30, 2022, as compared to a net loss of 9.1 million for the quarter ended June 30, 2021.
  • Basic and diluted loss per share was 0.07 for the quarter ended June 30, 2022, as compared to 0.17 per share for the quarter ended June 30, 2021.

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, June 2, 2022
NCNA, Colorectal cancer, Goal, Company, Protide, Forward-looking statement, Security (finance), U.S. Securities and Exchange Commission, Commencement (album), Therapy, GLOBE, Patient, Private Securities Litigation Reform Act, PD-1, Organic acid, NASDAQ, SEC, Neoplasm, Irinotecan, Bevacizumab, Cancer, Terminology, Pharmaceutical industry

As of March 31, 2022, NuCana had cash and cash equivalents of 52.6 million compared to 60.3 million as of December 31, 2021.

Key Points: 
  • As of March 31, 2022, NuCana had cash and cash equivalents of 52.6 million compared to 60.3 million as of December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 8.4 million for the quarter ended March 31, 2022, as compared to a net loss of 9.8 million for the quarter ended March 31, 2021.
  • Basic and diluted loss per share was 0.16 for the quarter ended March 31, 2022, as compared to 0.19 per share for quarter ended March 31, 2021.
  • Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements.

Comstock Reports Fiscal Year 2021 Results

Retrieved on: 
Thursday, March 31, 2022
XM, Private Securities Litigation Reform Act, Blackstone, Marketing, Risk, Forward-looking statement, GAAP, Reston Station, BLVD, CHCI, Commencement (album), LC, Comstock, Nasdaq, Securities & Exchange Commission of Pakistan, Adjustment, Annual report, Acquisition, Tunnel, Commercial property, D.C, Qualtrics

Secured buyer to complete divestiture of Comstock Environmental Services line of business (deal finalized on March 31, 2022).

Key Points: 
  • Secured buyer to complete divestiture of Comstock Environmental Services line of business (deal finalized on March 31, 2022).
  • Comstock is a leading developer and manager of mixed-use and transit-oriented properties in the Washington, D.C. metropolitan area.
  • Any number of important factors could cause actual results to differ materially from those in the forward-looking statements.
  • Comstock specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Wildpack Achieves Record Monthly Orders in February, Improving Over Best Month by 28%

Retrieved on: 
Monday, March 7, 2022
Marketing, Public expenditure, Record, TSX Venture Exchange, COVID, Accident, Wellness, VP, Aluminium, CFO, Meal, Forward-looking statement, Entrepreneurship, Technology, Commencement (album), News, Press release, Dispute resolution, SEO, Environment, Growth, Consumer health laws, Multimedia, ESG, Conference, CEO, CGO, COO, Benchmarking, COMAC, Review, OTCQB, Corporate services, Insurance, Investor relations, Online shopping, Video game, Cryptocurrency, Online gambling, Google, Health care, BC, Share (finance)

For the second consecutive month, orders eclipsed the previous monthly high.

Key Points: 
  • For the second consecutive month, orders eclipsed the previous monthly high.
  • New customers conversion reached a historical high of 30, a 20% increase over the previous monthly high.
  • Wildpack completed factory acceptance testing of two COMAC CFT 20 valve counter pressure fillers.
  • Wildpack's Las Vegas label and sleeve printing operations had record weekly commercial output during the month, and we anticipate full capacity in the second quarter of 2022.

Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook

Retrieved on: 
Monday, February 28, 2022
GLOBE, Proteomics, Health, Merck Group, Board, Growth, Proteogenomics, SCIEX, Investment, Security (finance), Center, SP100, Company, List of life sciences, Private Securities Litigation Reform Act, Chair, U.S. Securities and Exchange Commission, Commencement (album), Proteome, Software, Transformation, Seer, Business development, Forward-looking statement, Automation, Technology, Merck, CEO, Research, Rachel Haurwitz, SEC, Video game, Pharmaceutical industry, Film, Cryptocurrency

Gross profit, inclusive of grant revenue, was $1.4 million and gross margin was 47% for the fourth quarter of 2021.

Key Points: 
  • Gross profit, inclusive of grant revenue, was $1.4 million and gross margin was 47% for the fourth quarter of 2021.
  • Operating expenses were $21.3 million for the fourth quarter of 2021, as compared to $13.4 million for the corresponding prior year period.
  • Net loss was $19.7 million for the fourth quarter of 2021, as compared to $12.9 million for the corresponding prior year period.
  • Seer will host a conference call to discuss the fourth quarter and full year 2021 financial results on Monday, February 28, 2022 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.